Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03017742
Other study ID # SUNE0002
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date November 2016
Est. completion date December 11, 2017

Study information

Verified date June 2022
Source Masimo Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the clinical utility of triage screening for anemia and carbon monoxide poisoning (COP) in the ED setting.This is a prospective, nonrandomized, multi-center study of the performance of simultaneous non-invasive testing for two common disorders (COP and anemia). We will determine the limits of agreement and performance characteristics of non-invasive carboxyhemoglobin (SpCO) and hemoglobin (SpHb) values compared to standard blood tests for measurement of carboxyhemoglobin and hemoglobin, in the emergency department setting.


Recruitment information / eligibility

Status Terminated
Enrollment 813
Est. completion date December 11, 2017
Est. primary completion date December 11, 2017
Accepts healthy volunteers No
Gender All
Age group 1 Year and older
Eligibility Inclusion Criteria: - Age 1 year or older. - At least one digit has acceptable width as measured by study-provided digit gauge. - Presenting to emergency department for any complaint. - Potential for IV catheter and/or blood draw for CBC as standard of care. Exclusion Criteria: - Patients unable to consent for any reason - Patients with fingernail polish, discoloration or trauma to fingers

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Pulse Oximeter


Locations

Country Name City State
Turkey Tepecik Training and Research Hospital IEC Izmir

Sponsors (1)

Lead Sponsor Collaborator
Masimo Corporation

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference Between SpCO and COHb Measure the difference between noninvasive carboxyhemoglobin (SpCO) and carboxyhemoglobin determined by co-oximeter measurement of blood (COHb) as calculated in terms of standard deviation.
The average difference between paired Masimo noninvasive carboxyhemoglobin (SpCO) and reference carboxyhemoglobin (COHb) determined by co-oximeter measurement of blood represented as mean bias.
Up to 3 hours
Primary SpCO Detection of Carbon Monoxide Poisoning (COP) Diagnostics performance of SpCO for detecting COP measured by sensitivity and specificity compared to COHb. up to 3 hours
Primary Utility of SpCO as a Screening Tool for Carbon Monoxide Poisoning Surveying healthcare providers whether SpCO screening lead to identification of occult toxicity up to 3 hours
Primary Carbon Monoxide (CO) Elimination Pharmacokinetics in Relation to Oxygen Administration CO elimination will be evaluated as a function of administered oxygen. up to 3 hours
Primary Specificity of SpHb in Detecting Anemia. Specificity in detecting true non-anemic subjects as determined by co-oximeter reference analyzer. up to 3 hours
Primary Sensitivity of SpHb Detection of Anemia. Sensitivity in detecting true anemic subjects as determined by co-oximeter reference analyzer. up to 3 hours
Primary SpHb Utility for Screening Anemia Establish SpHb threshold that predicts the clinical outcome for acute treatment of anemia up to 3 hours
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Active, not recruiting NCT02101944 - Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Completed NCT01458028 - Age and Gender Effects on the Pharmacokinetics of BAY85-3934 Phase 1